Nature Study Unravels Toxicity and Resistance in WEE1 Inhibition

WEE1 inhibitors were long hailed as a precision weapon against TP53-mutant malignancies. Because these cancer cells rely heavily on WEE1 to preserve their G2 checkpoint, blocking WEE1 forces them into premature mitosis with unresolved DNA damage, triggering catastrophic cell death. While clinical trials demonstrated clear therapeutic efficacy, severe adverse effects forced multiple studies to halt—with the mechanistic source of this toxicity remaining elusive.

Recently, Alexis R. Barr’s team at Imperial College London published a research paper in Nature titled "WEE1 opposes APC/C^CDH1 activity to promote S phase entry," providing an overlooked explanation. WEE1 does not operate solely at the G2 checkpoint; it performs a vital, distinct role when cells exit quiescence (G0) to re-enter the active cell cycle by phosphorylating a protein called CDH1.

CDH1 serves as the activating subunit of the E3 ubiquitin ligase APC/C. The resulting APC/C^CDH1 complex acts as a primary molecular brake during the G1/S transition, continuously degrading proteins required for S-phase entry to keep cells tethered in G1. By phosphorylating key residues required for CDH1 to bind APC/C, WEE1 effectively releases this brake, allowing cells to exit G0 smoothly and execute the G1/S transition on schedule.

Figure 1. WEE1 couples CDK2 activity to G1/S. (Vuillemenot L A, et al., 2026)

When WEE1 is inhibited, APC/C^CDH1 becomes hyperactive prematurely. Cells emerging from quiescence fail to transition into S phase efficiently, leading to impaired G1/S progression, p21-dependent aberrant accumulation during S phase, and subsequent G2 arrest. Thus, WEE1 functions not only as a "checkpoint guardian" at G2, but also as an indispensable "initiator" during early cell-cycle progression. A single kinase orchestrates both phases via distinct downstream effectors: repressing CDK1 in G2, while restraining APC/C^CDH1 in G1.

This dual role resolves two persistent clinical enigmas:

• Why WEE1 inhibitors exhibit efficacy in TP53 wild-type tumors: Its function during G0/G1 re-entry operates independently of p53 status.
• Why these agents trigger severe systemic toxicity: Normal tissue homeostasis relies on the WEE1–CDH1 axis whenever quiescent cells re-enter the cell cycle for renewal and repair. Systemic WEE1 inhibition inevitably impairs physiological tissue regeneration and immune expansion.

Conversely, inhibiting APC/C^CDH1 or p21 sensitizes cells to WEE1 inhibitors, and cells with acquired resistance frequently downregulate both pathways, highlighting a plausible route for therapeutic evasion.

Several caveats remain: the mechanistic findings currently rely on cell-based models, and tissue-specific in vivo validation is still ongoing. Moreover, clinical toxicity is multifactorial, with the CDH1 pathway representing one critical dimension rather than the sole driver. Whether selective targeting of the WEE1–CDH1 interface can untangle efficacy from toxicity remains an open, long-term question.

Nonetheless, this study shifts the paradigm: WEE1 is no longer just a G2 checkpoint kinase, but a master switch governing the exit from cellular quiescence. Therapeutic efficacy and on-target toxicity are two sides of the same coin.